These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8995644)

  • 1. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
    Nieves A; Levy LS; Lenz J
    J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
    Zaiman AL; Nieves A; Lenz J
    J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
    Zaiman AL; Lenz J
    J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
    Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
    J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
    Amtoft HW; Sørensen AB; Bareil C; Schmidt J; Luz A; Pedersen FS
    J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
    Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
    J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.
    Pantginis J; Beaty RM; Levy LS; Lenz J
    J Virol; 1997 Dec; 71(12):9786-91. PubMed ID: 9371646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
    Ethelberg S; Hallberg B; Lovmand J; Schmidt J; Luz A; Grundström T; Pedersen FS
    J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
    Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
    J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
    Martiney MJ; Levy LS; Lenz J
    J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
    Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
    J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
    Lovmand J; Sorensen AB; Schmidt J; Ostergaard M; Luz A; Pedersen FS
    J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.
    Nielsen AA; Sørensen AB; Schmidt J; Pedersen FS
    J Virol; 2005 Jan; 79(1):67-78. PubMed ID: 15596802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells.
    LoSardo JE; Cupelli LA; Short MK; Berman JW; Lenz J
    J Virol; 1989 Mar; 63(3):1087-94. PubMed ID: 2644446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of substitution of simian virus 40 enhancer sequences into the Moloney murine leukemia virus (M-MuLV) long terminal repeat yields infectious M-MuLV with altered biological properties.
    Hanecak R; Pattengale PK; Fan H
    J Virol; 1988 Jul; 62(7):2427-36. PubMed ID: 2836623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
    Hallberg B; Schmidt J; Luz A; Pedersen FS; Grundström T
    J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.
    Starkey CR; Lobelle-Rich PA; Granger SW; Brightman BK; Fan H; Levy LS
    J Virol; 1998 Feb; 72(2):1078-84. PubMed ID: 9445002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
    Zaiman AL; Lewis AF; Crute BE; Speck NA; Lenz J
    J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regions of the Moloney murine leukemia virus genome specifically related to induction of promonocytic tumors.
    Wolff L; Koller R
    J Virol; 1990 Jan; 64(1):155-60. PubMed ID: 2403439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the significance of two single-base-pair differences in the SL3-3 and Akv virus long terminal repeats.
    Morrison HL; Dai HY; Pedersen FS; Lenz J
    J Virol; 1991 Feb; 65(2):1019-22. PubMed ID: 1846181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.